Abstracts feature clinical results demonstrating the high sensitivity of Biocept's Target Selector™ platform and the ability to identify mutations that may be missed by tissue biopsyClinical experience study evaluating 2,000 patient samples using Biocept's liquid biopsy tests shows detection of clinically actionable lung cancer mutations consistent with published prevalence rates"AND" marketing campaign highlights the benefits of using both liquid biopsy and tissue biopsy to improve the chances of rapidly identifying clinically actionable biomarkers in cancer patients
- Billable test volume in first quarter 2017 increases 38% over prior-year period- Revenue of $1.68 million includes impact of conversion to accrual-based revenue recognition- Enters into commercial collaborations with two major oncology treatment centers- Signs agreement to provide liquid biopsy testing in landmark clinical trial with ALCMI- Strengthens balance sheet supporting sales force expansion intended to accelerate growth- Company to host conference call at 4:30 p.m. Eastern time today
Large prospective multi-center clinical trial designed to evaluate the impact of cancer biomarker detection and serial monitoring using liquid biopsy to improve the outcomes of patients with lung cancerPatient-founded research consortium of 25 global oncology centers to create large, well-annotated, uniformly collected biorepository of lung cancer patient blood samples
SAN DIEGO , May 3, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it will release financial results for the
New patent provides broad coverage for the use of antibodies to capture targets of interest, including circulating tumor cells (CTCs) and other materials shed by solid tumors into the blood stream
NCI-designated cancer institute with leading molecular pathology lab obtains rights to utilize and commercially offer Biocept's Target Selector™ liquid biopsy services throughout the state of OregonKnight Diagnostic Laboratories to work with Biocept to co-develop highly sensitive, multiplexed assay panels leveraging OHSU's next generation sequencing (NGS) expertise
SAN DIEGO , March 31, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W.
SAN DIEGO , March 28, 2017 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, today announced that it has entered into securities purchase agreements with certain
